MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.70
-0.29
-1.26%
Opening 13:03 11/14 EST
OPEN
23.06
PREV CLOSE
22.99
HIGH
23.25
LOW
22.24
VOLUME
236.37K
TURNOVER
--
52 WEEK HIGH
32.46
52 WEEK LOW
17.80
MARKET CAP
1.12B
P/E (TTM)
-10.6543
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EDIT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EDIT News

  • Editas adds to Celgene collaboration-stoked up move, shares ahead 4%
  • Seeking Alpha - Article.1d ago
  • Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
  • Zacks.1d ago
  • Editas Expands Its Celgene Partnership After Another Strong Quarter
  • MotleyFool.com.1d ago
  • Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.1d ago

More

Industry

Biotechnology & Medical Research
-0.06%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About EDIT

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
More

Webull offers Editas Medicine Inc (EDIT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.